论文部分内容阅读
目的探讨三种喹诺酮类药物在治疗呼吸道感染中的成本和疗效。方法对85例入选患者,按不同的治疗方案随机分入左氧氟沙星、加替沙星和莫西沙星三组,分析各组成本及评价其疗效。结果莫西沙星组治愈率较左氧氟沙星和加替沙星组明显提高(P<0.05),但各组的不良反应发生率及疗效成本分析无显著差异(P>0.05)。结论莫西沙星治疗呼吸道感染的疗效最佳。
Objective To investigate the cost and efficacy of three quinolones in the treatment of respiratory tract infections. Methods Totally 85 patients were enrolled and randomly divided into three groups according to different treatment regimens: levofloxacin, gatifloxacin and moxifloxacin. The cost of each group was analyzed and its efficacy was evaluated. Results The cure rate of moxifloxacin group was significantly higher than that of levofloxacin and gatifloxacin group (P <0.05). However, there was no significant difference in the incidence of adverse reactions and cost-effectiveness between each group (P> 0.05). Conclusion Moxifloxacin has the best curative effect on respiratory tract infection.